The past year has been transformative for IPF, with new therapies, emerging mechanisms, and evolving patient management strategies reshaping the landscape. This panel will provide a strategic, forward-looking overview of how the field has progressed and what the next 12-18 months may hold. Panellists will discuss the expanding pathophysiology of IPF, emerging classifications of therapies, and implications for patient care, clinical development strategy, and communication with stakeholders.

Key Discussion Points:

• How newly approved therapies and emerging candidates are expected to influence IPF treatment and clinical and research priorities in the next 12–18 months.
• Exploring the practical impact of emerging terminology, anti-fibrotic, anti-inflammatory, de-differentiation, fibrolysis, and how these distinctions may shape patient and clinician preferences
• Approaches for ordering, timing, and combining therapies in a multi-drug era, balancing efficacy, safety, and operational feasibility.
• Identifying opportunities, challenges, and areas for collaboration to ensure trials and programs remain aligned with evolving clinical practice